Publication

Article

Pharmacy Times

April 2017 Respiratory Health
Volume83
Issue 4

Smokers Remain Underscreened for Lung Cancer

Lung cancer screening rates among this high-risk population remained alarmingly low.

In 2013, the United States Preventive Services Task Force (USPSTF) recommended that all patients aged 55 to 80 years with at least a 30 pack- year smoking history be screened for lung cancer using low-dose computed tomography. Several years later, however, lung cancer screening rates among this high-risk population remained alarmingly low, according to the results of a recent study.

The study, conducted by American Cancer Society investigators and pub- lished in JAMA Oncology, compared National Health Interview Survey responses from 2010 with those from 2015, focusing on patients who met the requirements for screening under the USPSTF recommendations. The researchers found that despite the recommendations, only 3.9% of eligible patients were screened in 2015 com- pared with 3.3% in 2010. Based on their analysis, the study authors determined that only 262,700 current and former smokers were screened in 2015 out of 6.8 million eligible patients.

“The reasons for the low uptake in screening are probably varied and likely include lack of knowledge among both smokers and doctors as to screening recommendations as well as access to high-quality screening,” said Ahmedin Jemal, DVM, PhD, in a press release. “Our previous study showed implementing quality screening broadly across the United States could prevent about 12,000 lung cancer deaths every year in the short term. But we cannot prevent those deaths until, and unless, we start educating eligible smokers as well as clinicians about the benefits and risks of screening so patients can make an informed decision.”

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
Image Credit: © Krakenimages.com - stock.adobe.com